You are here: Industry Insights > InnoCare

News List

Chinese BTK Inhibitor Orelabrutinib Gone Global, What Other Drugs Have Been Ok'd Overseas in 2021 PharmaSources/Dopine
July 26, 2021
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China PharmaSources
August 21, 2025
InnoCare Pharma announced today that the first patient has been dosed in the registrational trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) for patients with BTK inhibitor treated mantle cell lymphoma (MCL) in China.
InnoCare Releases 2025 Interim Results and Business Highlights PharmaSources
August 20, 2025
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025.
InnoCare Announces FDA Approval of Clinical Trial for BCL2 Inhibitor Mesutoclax in AML and MDS PharmaSources
July 14, 2025
July 14, 2025 ，InnoCare Pharma announced that FDA has approved the Investigational New Drug application to conduct the clinical trial of BCL2 inhibitor mesutoclax in combination with azacitidine for the treatment of myeloid malignancies.
Data of InnoCare’s Robust Hemato-Oncology Pipelines Presented at the European Hematology Association (EHA) 2025 Congress PharmaSources
June 13, 2025
InnoCare’s robust oncology pipelines were presented at the ongoing European Hematology Association (EHA) 2025 Congress.
InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China PharmaSources
May 16, 2025
InnoCare Pharma announced today that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment patients with non-segmental vitiligo in China.
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA PharmaSources
May 06, 2025
InnoCare Pharma announced today that its new generation pan-TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the CDE of China NMPA.
InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China PharmaSources
April 27, 2025
InnoCare Pharma announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.
InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China PharmaSources
April 16, 2025
InnoCare's zurletrectinib NDA for treating NTRK fusion - positive advanced solid tumors in adults and adolescents was accepted. It shows good efficacy and safety.
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for CLL/SLL Patients in China PharmaSources
March 28, 2025
InnoCare announced the first patient dosed in the Phase III trial of ICP-248 combined with orelabrutinib for CLL/SLL. It's a potential treatment, with other trials advancing.